Audits of radiopharmaceutical formulations.
A procedure for auditing radiopharmaceutical formulations is described. To meet FDA guidelines regarding the quality of radiopharmaceuticals, institutional radioactive drug research committees perform audits when such drugs are formulated away from an institutional pharmacy. All principal investigators who formulate drugs outside institutional pharmacies must pass these audits before they can obtain a radiopharmaceutical investigation permit. The audit team meets with the individual who performs the formulation at the site of drug preparation to verify that drug formulations meet identity, strength, quality, and purity standards; are uniform and reproducible; and are sterile and pyrogen free. This team must contain an expert knowledgeable in the preparation of radioactive drugs; a radiopharmacist is the most qualified person for this role. Problems that have been identified by audits include lack of sterility and apyrogenicity testing, formulations that are open to the laboratory environment, failure to use pharmaceutical-grade chemicals, inadequate quality control methods or records, inadequate training of the person preparing the drug, and improper unit dose preparation. Investigational radiopharmaceutical formulations, including nonradiolabeled drugs, must be audited before they are administered to humans. A properly trained pharmacist should be a member of the audit team.
Castronovo
F P
FP
Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115.
D001900:Boston; D002626:Chemistry, Pharmaceutical; D004282:Documentation; D015507:Drugs, Investigational / Q000592:standards*; D005568:Forms and Records Control; D006801:Humans; D010606:Pharmacy and Therapeutics Committee; D011786:Quality Control; D011868:Radioisotopes; D014481:United States; D014486:United States Food and Drug Administration
D015507:Drugs, Investigational; D011868:Radioisotopes